A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
// Paolo D’Arrigo 1, * , Michele Russo 1, * , Anna Rea 1 , Martina Tufano 1 , Elia Guadagno 2 , Maria Laura Del Basso De Caro 2 , Roberto Pacelli 2 , Felix Hausch 3 , Stefania Staibano 2 , Gennaro Ilardi 2 , Silvia Parisi 1 , Maria Fiammetta Romano 1 and Simona Romano 1 1 Department of Molecular Medicine and Medical Biotechnologies, Federico II University, Naples, Italy 2 Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy 3 Technical University Darmstadt Institute of Organic Chemistry and Biochemistry, Darmstadt, Germany * These authors have contributed equally to this work Correspondence to: Maria Fiammetta Romano, email: mariafiammetta.romano@unina.it , romano@dbbm.unina.it Keywords: PD-L1, glioblastoma multiforme, FKBP51, ionizing radiation, SAFit Received: March 10, 2017 Accepted: June 11, 2017 Published: July 17, 2017 ABSTRACT Background: FKBP51 is a co-chaperone with isomerase activity, abundantly expressed in glioma. We previously identified a spliced isoform (FKBP51s) and highlighted a role for this protein in the upregulation of Programmed Death Ligand 1 (PD-L1) expression in melanoma. Because gliomas can express PD-L1 causing a defective host anti-tumoral immunity, we investigated whether FKBP51s was expressed in glioma and played a role in PD-L1 regulation in this tumour. Methods: We used D54 and U251 glioblastoma cell lines that constitutively expressed PD-L1. FKBP51s was measured by immunoblot, flow cytometry and microscopy. In patient tumours, IHC and qPCR were used to measure protein and mRNA levels respectively. FKBP51s depletion was achieved by siRNAs, and its enzymatic function was inhibited using selective inhibitors (SAFit). We investigated protein maturation using N-glycosidase and cell fractionation approaches. Results: FKBP51s was expressed at high levels in glioma cells. Glycosylated-PD-L1 was increased and reduced by FKBP51s overexpression or silencing, respectively. Naïve PD-L1 was found in the endoplasmic reticulum (ER) of glioma cells complexed with FKBP51s, whereas the glycosylated form was measured in the Golgi apparatus. SAFit reduced PD-L1 levels (constitutively expressed and ionizing radiation-induced). SAFit reduced cell death of PBMC co-cultured with glioma. Conclusions: Here we addressed the mechanism of post-translational regulation of PD-L1 protein in glioma. FKBP51s upregulated PD-L1 expression on the plasma membrane by catalysing the protein folding required for subsequent glycosylation. Inhibition of FKBP51s isomerase activity by SAFit decreased PD-L1 levels. These findings suggest that FKBP51s is a potential target of immunomodulatory strategies for glioblastoma treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291 · cited 1×
“However, some available data suggest that patients with higher levels of PD-L1 expression have an improved response rate to immunotherapy and progression-free survival [8].”
BackgroundSelective inhibitors of the FK506-binding protein 51 by induced fit
Gaali, S., Kirschner, A., Cuboni, S., Hartmann, J., Kozany, C., Balsevich, G., Namendorf, C., Fernandez-Vizarra, P., Sippel, C., Zannas, A. S., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1699 · Cited by 245 · cited 2×
“More recently, potent and specific inhibitors of FKBP51 have been created and named SAFit 1 and 2 because of their selectivity through an “induced fit” mechanism [26].”
BackgroundSelf-citationAntonios, J. P., Soto, H., Everson, R. G., Moughon, D., Orpilla, J. R., Shin, N. P., Sedighim, S., Treger, J., Odesa, S., Tucker, A., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now287 · Cited by 206
FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition
Baughman, G., Wiederrecht, G. J., Campbell, N. F., Martin, M. M., & Bourgeois, S. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4395 · Cited by 173
Periyasamy, S., Hinds, T., Shemshedini, L., Shou, W., & Sanchez, E. R. (2010) · Oncogene · doi:10.1038/onc.2009.458 · Cited by 108
Jiang, W., Cazacu, S., Xiang, C., Zenklusen, J. C., Fine, H. A., Berens, M., Armstrong, B., Brodie, C., & Mikkelsen, T. (2008) · Neoplasia · doi:10.1593/neo.07929 · Cited by 88 · cited 2×
“FKBP5 encodes a large immunophilin which was originally cloned in lymphocytes [17] but also found abundantly expressed in several tumours [18–23], including glioblastoma [24].”
Background
Cited by
Mechanisms Controlling PD-L1 Expression in Cancer
Cha, J.-H., Chan, L.-C., Li, C.-W., Hsu, J. L., & Hung, M.-C. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.030 · Cited by 1,045
Regulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 535
Yamaguchi, H., Hsu, J.-M., Yang, W.-H., & Hung, M.-C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 493
Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy
Hsu, J.-M., Li, C.-W., Lai, Y.-J., & Hung, M.-C. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1892 · Cited by 286
Metadata
- Authors
- D’Arrigo, P., Russo, M., Rea, A., Tufano, M., Guadagno, E., Del Basso De Caro, M. L., Pacelli, R., Hausch, F., Staibano, S., Ilardi, G., Parisi, S., Romano, M. F., & Romano, S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-07-17
- Volume
- 8
- Issue
- 40
- Pages
- 68291-68304
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2744433099
- Cited by
- 99
- References
- 6
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.